Gilead Sciences, Inc. (GILD) Position Lowered by Carlton Hofferkamp & Jenks Wealth Management LLC

Carlton Hofferkamp & Jenks Wealth Management LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 47.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 5,254 shares of the biopharmaceutical company’s stock after selling 4,700 shares during the quarter. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Gilead Sciences were worth $371,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. lifted its stake in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 267 shares in the last quarter. Penserra Capital Management LLC lifted its stake in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 144 shares in the last quarter. Webster Bank N. A. lifted its stake in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 624 shares in the last quarter. Finally, American Beacon Advisors Inc. acquired a new position in shares of Gilead Sciences in the first quarter worth about $143,000. Institutional investors and hedge funds own 74.05% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Position Lowered by Carlton Hofferkamp & Jenks Wealth Management LLC” was first published by Equities Focus and is the sole property of of Equities Focus. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.equitiesfocus.com/2017/09/17/gilead-sciences-inc-gild-position-lowered-by-carlton-hofferkamp-jenks-wealth-management-llc.html.

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up 0.09% during midday trading on Friday, hitting $82.36. The stock had a trading volume of 12,401,948 shares. Gilead Sciences, Inc. has a 52 week low of $63.76 and a 52 week high of $86.27. The stock has a 50-day moving average of $77.16 and a 200 day moving average of $70.20. The stock has a market cap of $107.56 billion, a PE ratio of 8.95 and a beta of 1.19.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm had revenue of $7.14 billion during the quarter, compared to analyst estimates of $6.35 billion. During the same period last year, the firm posted $3.08 earnings per share. Gilead Sciences’s revenue for the quarter was down 8.2% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post $8.75 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Investors of record on Friday, September 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.53%. The ex-dividend date is Thursday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 22.58%.

Several research analysts recently commented on GILD shares. William Blair reiterated an “outperform” rating on shares of Gilead Sciences in a research note on Friday, June 16th. Morgan Stanley restated an “equal weight” rating on shares of Gilead Sciences in a research note on Tuesday, July 11th. Royal Bank Of Canada assumed coverage on Gilead Sciences in a research note on Thursday. They set an “outperform” rating and a $94.00 price objective on the stock. Robert W. Baird restated an “outperform” rating and set a $87.00 price objective on shares of Gilead Sciences in a research note on Tuesday, August 29th. Finally, Berenberg Bank set a $86.00 price objective on Gilead Sciences and gave the company a “buy” rating in a research note on Tuesday, August 29th. Eleven investment analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $83.79.

In related news, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction on Thursday, September 7th. The shares were sold at an average price of $85.00, for a total value of $4,404,700.00. Following the completion of the transaction, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at $3,684,920. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The disclosure for this sale can be found here. Over the last three months, insiders sold 466,819 shares of company stock valued at $36,740,240. 1.30% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply